CombiMatrix to Collaborate with the Washington Animal Disease Diagnostic Laboratory (WADDL) on USA's National Early Detection System for Avian Influenza.

NEWPORT BEACH, Calif. -- WADDL is One of Approximately 48 Labs in the U.S. That is Certified for Influenza Testing

E[acute accent]Acacia Research Corporation (Nasdaq:CBMX)(Nasdaq:ACTG) announced today that its CombiMatrix group will collaborate with the Washington Animal Disease Diagnostic Laboratory (WADDL) on influenza testing. A broad interagency effort is being undertaken to monitor the Pacific Flyway, to determine if the seasonal migration of birds will bring the highly pathogenic Eurasian strain of Avian Influenza (AI: H5N1) into North America and the United States. This effort is being coordinated by the US Department of Agriculture, Department of the Interior, and the Department of Health and Human Services in collaboration with State regulatory agencies. E[acute accent]The Pacific Flyway includes Alaska, Western Canada, and the West Coast of the United States including Washington State. There is concern that the seasonal migration of birds will bring the pathogenic Eurasian H5N1 avian flu into this region of the world through the Pacific Flyway. E[acute accent]The current validated protocol for verification of a pathogenic influenza strain requires performing an initial PCR (polymerase chain reaction) to determine the existence of matrix protein gene, which is common to all Influenza A infections. If matrix protein is present, then a successive PCR for hemagglutinin is performed to determine if the H5 gene is also present. While this part of the procedure can be completed quickly, verification and further typing after a positive result requires that the sample be cultured and sequenced, necessitating roughly another week or more to complete. CombiMatrix's influenza monitoring system has shown in laboratory tests that it can confirm and type the infection in four hours. Our goal in this study is to demonstrate that our system produces quick virus typing results in the diagnostic laboratory environment that correlate to the standard protocol. E[acute accent]"Our Influenza Surveillance Technology has been validated in our laboratory in collaboration with the World Health Organization. We now seek to validate the system in the field in collaboration with WADDL," stated Dr. Amit Kumar, President and CEO of CombiMatrix Corporation. "We are pleased that two Washington State organizations can function together to address this potential animal and public health concern." E[acute accent]"We look forward to working with CombiMatrix to determine if their technology can enable more rapid typing of influenza viruses from animals," said Dr. Terry McElwain, DVM, Ph.D., Professor and Executive Director of WADDL, and Director of Animal Health Research Center at the College of Veterinary Medicine, Washington State University. "While official verification of a highly pathogenic strain of influenza will require virus isolation initially, completing a test that can type the virus in four hours would be a significant advance over the conventional approach in monitoring spread of infection once an outbreak has been confirmed."

E[acute accent]ABOUT WADDL

E[acute accent]The Washington Animal Disease Diagnostic Laboratory (WADDL) is a publicly supported laboratory located in the College of Veterinary Medicine at Washington State University. With two locations in Pullman and Puyallup, the WADDL provides disease surveillance in animal, food, and environmental samples. WADDL was one of the 12 founding members of the National Animal Health Laboratory Network, and routinely performs diagnostic assays to detect disease agents such as avian influenza and BSE.

E[acute accent]ABOUT ACACIA RESEARCH CORPORATION

E[acute accent]Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group. E[acute accent]The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology. E[acute accent]The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 42 patent portfolios, which include over 160 U.S. patents, and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT(R)), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS, image resolution enhancement, interactive data sharing, interactive television, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging, spreadsheet automation, user activated Internet advertising and web conferencing & collaboration software. E[acute accent]Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups. E[acute accent]Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.

E[acute accent]Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

E[acute accent]This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.